All News
Filter News
Found 324 articles
-
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
8/1/2022
HUTCHMED Limited announces that it has initiated a bridging study of tazemetostat in China.
-
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918
6/30/2022
Ascentage Pharma announced that its novel inhibitor of the embryonic ectoderm development protein, APG-5918, has been cleared by the US Food and Drug Administration to enter a first-in-human study that will assess the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malignancies.
-
Ipsen announced it is acquiring the company and its cancer drugs, including Tazverik, which were approved for two different indications by the FDA in 2020.
-
Ipsen to acquire Epizyme, expanding its portfolio in oncology
6/27/2022
Ipsen and Epizyme announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme.
-
HTG Technology Featured in Multiple Scientific Abstracts Highlighting Novel Applications in Precision Medicine at ASCO 2022
6/6/2022
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced its HTG EdgeSeq technology was highlighted in multiple scientific abstracts at the 2022 American Society of Clinical Oncology (ASCO) conference held in Chicago, Illinois.
-
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
-
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
6/2/2022
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R 2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting.
-
HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China
6/1/2022
HUTCHMED Limited announces that TAZVERIK® has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma and follicular lymphoma consistent with the label as approved by the U.S. Food and Drug Administration.
-
Civetta Therapeutics Appoints Jesse Smith, Ph.D. as CSO and Susan Ashwell, Ph.D. as SVP of Chemistry
5/17/2022
Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, today announced that it has strengthened its management team with the additions of Jesse Smith, Ph.D., as Chief Scientific Officer and Susan Ashwell, Ph.D., as SVP of Chemistry.
-
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
5/10/2022
Epizyme today reported first quarter 2022 financial results and provided a business update.
-
AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
4/13/2022
Ascentage Pharma announced that it has presented the latest results from six preclinical studies of the company's five investigational drug candidates: the Bcl-2 inhibitor lisaftoclax and the MDM2-p53 inhibitor alrizomadlin, two key candidates in the company's apoptosis-targeted pipeline, as well as the FAK inhibitor APG-2449, the EED inhibitor APG-5918 and the KRAS inhibitor APG-1842, at the 2022 American Association for Cancer Research Annual Meeting.
-
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/16/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and full year 2021.
-
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
3/15/2022
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update.
-
HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
3/3/2022
HUTCHMED Limited reports its audited financial results for the year ended December 31, 2021 and provides updates on key clinical and commercial developments since the start of 2022.
-
Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
3/1/2022
Epizyme today reported fourth quarter and full year 2021 financial results and provided business and portfolio updates.
-
Global Top 10 Cancer Drugs By Sales 2021
2/14/2022
Despite considerable advancement in the field of cancer therapy, cancer remains the leading cause of death worldwide.
-
Daiichi wants to maximize its investment in three antibody-drug conjugates, which the company has positioned as one of the strategic pillars of its 5-year Business Plan.
-
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China
1/10/2022
HUTCHMED Limited has initiated a Phase I study in China of HMPL-760, a highly potent, selective, and reversible inhibitor with long target engagement against Bruton’s tyrosine kinase, including wild-type and C481S-mutated BTK.
-
Foghorn Therapeutics Announces Chief Scientific Officer Succession
1/10/2022
Foghorn® Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced Steven Bellon, Ph.D., currently Senior Vice President of Drug Discovery, is promoted to Chief Scientific Officer, effective, January 10, 2022.
-
Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates
1/10/2022
Epizyme today provided an update on recent business highlights and its outlook for 2022.